Press release content from News Direct Corporation. The AP news staff was not involved in its creation.
Algernon Pharmaceuticals forms Algernon NeuroScience subsidiary to advance DMT stroke program
PRESS RELEASE: Paid content from News Direct Corporation
Press release content from News Direct Corporation. The AP news staff was not involved in its creation.January 4, 2023 GMT
Algernon Pharmaceuticals CEO Christopher Moreau joined Proactive to share news that the company has decided to move its psychedelic DMT stroke program into a private company called Algernon NeuroScience. Moreau said AGN Neuro will stay private until it has advanced through to the completion of a Phase 2a stroke study planned for Q4, 2023. Following that, the company will consider a potential direct IPO listing on the NASDAQ.
View original content to download multimedia: https://newsdirect.com/news/algernon-pharmaceuticals-forms-algernon-neuroscience-subsidiary-to-advance-dmt-stroke-program-936820961